iCo and CPDD get funding for parasitic drug development alliance
25 September 2009
Sukaina Virji
Please Login to read the full article.
25 September 2009
Sukaina Virji
sukaina.virji@informa.com
iCo Therapeutics of Canada has signed a collaboration agreement with The Consortium for Parasitic Drug Development (CPDD) to research and develop iCo's oral drug delivery technology for the treatment of neglected diseases such as leishmaniasis and trypanosomiasis.
The technology was used...
Please Login to read the full article.
RELATED CONTENT
NEWS
- WHO hopes Gilead's expanded support for leishmaniasis control will encourage others
- Genzyme and Isis report updated mipomersen results, as firms prepare for filings
- SMC vetoes Sanofi's Jevtana, AZ's Vimovo and Merck's Emend, but OKs Simponi again
- Sanofi and DNDi to tackle nine neglected diseases
COMMENT
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
